

Index

Note: Page numbers in “*italics*” represent figures and “**bold**” page number represents tables in text.

a

- absorption of drugs 1–2, **2**
 - advantages 1
 - definition 1
 - disadvantages 1
 - impact of a drug's pK_a 1, **2**
 - in gastrointestinal tract (GI) 2
 - ionized form 1
 - non-ionized form 1
 - of topical and transdermal
 - formulations of drugs 2
 - via oral mucosal surface 2
- AChE inhibitors *see*
 - acetylcholinesterase inhibitors
- acepromazine 179, 226, 243, 333
 - clinical uses
 - in dogs and cats 56
 - horses 56
 - pigs 57
 - in ruminants 57
 - effects on organ systems 57
 - metabolism 55–56
 - pharmacokinetics 55–56
- acetaminophen 14, 139–142
- acetazolamide 316, 317
- acetylcholinesterase (AChE) inhibitors
 - calabadiol 218
 - clinical use 216–217
 - edrophonium 215–217, **217**
 - effects on organ systems 217–218
 - mechanism of action 215
 - metabolism 216
 - neostigmine 215–217, **217**
 - pharmacokinetics 216
 - physostigmine 217
 - sugammadex 218
- acidic drugs 2
- adrenergic receptors
 - α_1 adrenoceptors 221
 - α_2 adrenoceptors, 221–222
 - see also* α_2 –adrenergic receptor
 - β_1 adrenoceptors, 222 *see also*
 - β –adrenergic receptors
 - β_2 adrenoceptors 222
 - β_3 adrenoceptors 222
 - location and effects of 222, **223**
- agonist-antagonists 10, 86
- albuterol (salbutamol) 231
- alfaxalone
 - cardiovascular effects 109
 - central nervous system
 - effects 109–110
 - clinical uses 109, **109**
 - contraindications 110
 - drug interactions 110
 - mechanism of action 108
 - metabolism of 109
 - myoclonus 110
 - pharmacokinetics 108–109
 - respiratory depressant effects 109
- α_2 –adrenergic receptor *see also*
 - α_2 –receptor agonists;
 - α_2 –receptor antagonists
- G-protein coupled receptors
 - (GPCRs) 36
- pre-synaptic α_2 receptors 36
- subtypes 36
- α_2 adrenoceptor
 - agonists 36–44, 303–304
- alpha-chloralose 115
- α_2 –receptor agonists **39**
 - cardiovascular effects 38
- clonidine 39
- contraindications 39
- detomidine 40–41
- dexmedetomidine 42–43
- diuresis 38
- gastrointestinal (GI) effects 39
- medetomidine 41–42
 - with pre-synaptic receptors 36, 37
- renal blood flow (RBF) 38
- respiratory effects 38
- romifidine 43–44
- sedative and analgesic effects 36–38
- xylazine 40
- α_2 –receptor antagonists
 - atipamezole 45
 - tolazoline 44–45
 - vatinoxan 45
 - yohimbine 44
- amantadine 305–306
- amide-linked local anesthetics **166**
 - bupivacaine 167–168
 - lidocaine 167
 - mepivacaine 167
 - ropivacaine 167
- aminosteroids 208, 209
- amiodarone 260–261
- amitriptyline 285, 307
- amlodipine 242–243, 263
- angiotensin converting enzyme (ACE)
 - inhibitors 240–241
- angiotensin II receptor
 - blockers 241–242
- Animal Medical Drug Use
 - Clarification Act (AMDUCA)
 - of 1994 32, 35
- antacids 259, 352–353

- antiarrhythmic drugs
 - class IA drugs
 - procainamide 256
 - quinidine 255–256
 - class IB drugs
 - lidocaine 257
 - mexiletine 257–258
 - phenytoin 258
 - class IC drugs
 - flecainide 258
 - propafenone 258
 - classification of 252, **253–254**
 - class II antiarrhythmic drugs 259–260
 - class III antiarrhythmic drugs 260–261
 - class IV antiarrhythmic drugs 261–262
 - digoxin 262
 - mechanism of action 252
 - proarrhythmia 255
 - use dependence 252, 255
 - anticholinergics
 - atropine 171, 172, 173, **173**
 - doses of 174, **174**
 - glycopyrrolate 171, 172, 173, **173**
 - mechanism of action 171
 - muscarinic receptor 171, **172**
 - with other drugs 174–175
 - pharmacodynamics 173–174
 - anticonvulsant medications 304–305
 - antiemetics
 - maropitant 350–351, **351**
 - ondansetron 351–352
 - anti-epileptic drugs 23
 - acepromazine 333
 - benzodiazepine (BZ)
 - drugs 332–333, **333**
 - emergency control of
 - seizures 333–334
 - gabapentin 331–332
 - ketamine 333
 - levetiracetam (LV) 329–330
 - maintenance
 - anticonvulsants 324, **325**
 - phenobarbital (PB)
 - clinical use and efficacy 326
 - cost and availability 325
 - drug interactions 327–328
 - mechanism of action 325
 - pharmacokinetics 325–326
 - side effects 327
 - toxicity 327
 - potassium bromide (KBr) 328–329
 - sedative effects 324
 - seizure control 324
 - topiramate 331
 - zonisamide (ZN) 330–331
 - anti-glial medications 309–310
 - antihistamines
 - contraindications 344–345
 - mechanism of action
 - H1 receptors 339–340
 - H2 receptor 340
 - H3 receptor 340
 - H4 receptor 340–341
 - pharmacokinetics
 - clinical use 342–343
 - H1 antihistamines 341
 - H2-receptor antagonists 341–342
 - metabolism 342
 - side effects
 - cardiovascular effects 344
 - CNS effects 343
 - pulmonary effects 343–344
 - antihypertensive drugs
 - acepromazine 243
 - angiotensin converting enzyme (ACE) inhibitors 240–241
 - angiotensin II receptor
 - blockers 241–242
 - β -adrenergic receptors blockers 243
 - calcium channel blocker 242–243
 - diuretics 243
 - magnesium sulfate 243
 - sympatholytic drugs 236–240
 - vasodilators 243
 - apneic index 131, **132**
 - apparent volume of
 - distribution (V) 3–4
 - aquaretics 322
 - aspirin 139, 140, 142–143
 - Assessment of Blood Consumption
 - Score (ABC score) 388
 - atenolol 259–260
 - atipamezole 45
 - atracurium 207, **208**, 209
 - azaperone 56, 57
- b**
- barbiturates 97, 267, 269, 271
 - acute tolerance 102
 - compartmental pharmacokinetic model 98
 - crystal deposition 102
 - in human medicine 96
 - mechanism of action 100
 - metabolism 99–100
 - methohexital 96–100, 103–104
 - oxybarbiturates 96, 100
 - pentobarbital 96, 97, 104
 - pharmacodynamics
 - cardiovascular effects 101
 - cerebral metabolism
 - effects 100–101
 - respiratory effects 101–102
 - pharmacokinetics 98–99
 - pharmacology 96
 - phenobarbital 96, 97, 102
 - physicochemical
 - characteristics 96–98
 - protein binding of 98
 - thiamylal 96
 - thiobarbiturates 96, 98
 - thiopental 96–103, 98
 - zero-order Michaelis-Menten kinetics 98
 - behavior drugs
 - benzodiazepines 288–289
 - β -adrenergic antagonists 291–293
 - buspirone 291
 - clonidine 293–294
 - discontinuation syndrome 296, **296**
 - gabapentin 294–295
 - methylphenidate 295–296
 - monoamine oxidase inhibitors (MAOIs) 287–288
 - selective serotonin reuptake inhibitors (SSRIs) 283–285
 - trazodone 289–291
 - tricyclic antidepressants **285**, 285–287
 - benazepril 241
 - benzodiazepines (BZ) drugs 183, 288–289, 332–333, **333**
 - agonists 60
 - amnesic effects 66
 - analgesic effects 67–68
 - anesthetic sparing 65
 - anticonvulsants 65–66
 - appetite stimulation 66
 - behavior pathologies
 - management 60
 - cardiovascular side effects 66
 - central nervous system
 - effects 65–66
 - diazepam 187, 192, **193**
 - anticonvulsant tolerance 68
 - in cats 190–191

benzodiazepines (BZ) drugs (*cont'd*)

dog metabolism 190
 empirical formula 67
 in humans 189
 legal status 67
 limitations of 67
 oral administration of 67
 pharmacokinetics in various species 62, **63**
 posology of 68, **68**
 rectal administration of 66
 in small ruminants 197
 US veterinary labeled products 67
 drug interactions 192
 excretion 65
 flumazenil 60, 66, 70, 197
 interaction with GABA_A receptors 60–62, 62, 187, 187, 188
 inverse agonists 60
 lorazepam (Ativan)
 chemical name (IUPAC) 69
 elimination half time 189
 empirical formula 69
 legal status 69
 onset of action 189
 pharmacokinetics in various species 62, **64**
 posology of **68**, 69
 US veterinary labeled products 69
 metabolic pathways 65
 midazolam 187, 192, **193**
 advantage 69
 in alpacas 191, 197
 in cats 190, 193, 195
 chemical name (IUPAC) 68
 clinical efficacy of 65
 in dogs 190, 193–195
 empirical formula 68
 in horses 191, 196
 in humans 189
 intranasal administration of 66
 intranasal bioavailability of 65
 legal status 69
 pharmacokinetics in various species 62, **64**
 posology of **68**, 69
 in rabbits 195–196
 in rodents 195–196
 in small mammals 195–196
 in small ruminants 197

US veterinary labeled products 69
 molecular structure of 60, 61
 muscle relaxation 66
 in neonatal foals 196
 oxazepam 187, 189
 paradoxical effects 65
 pH 60, **61**
 pharmacodynamics 191–192
 pharmacokinetics 188–189
 pharmacologic effects 187
 phase I oxidase reactions 189
 phase II oxidase reactions 189
 pKa 60, **61**
 protein binding 65
 remimazolam (CNS 7056) 69–70, 187
 reproductive/nursing safety 192
 respiratory side effects 66
 routes of administration 62, **63–64**, 65, 66
 sedative effects 65
 temazepam 187
 uses 192
 water solubility 60, **61**
 zolazepam 60
 benzyloquinolinium
 aminosteroids 209
 atracurium 207, 209
 cisatracurium 207, 209
 mechanism of action 207
 metabolism 207
 mivacurium 208
 rocuronium 210–211
 vecuronium 210
 β-adrenergic antagonists
 clinical use 292
 contraindications 292
 drug interactions 292
 effect on patients under general anesthesia 292–293
 effects on organ systems 292
 mechanism of action 291
 metabolism 292
 pharmacokinetics 292
 sodium retention 292
 β-adrenergic receptors, 36, 243 *see also*
 beta₁ and beta₂ adrenergic receptors
 blood and blood products
 albumin 387
 Assessment of Blood Consumption Score (ABC score) 388

blood component therapy 382
 blood transfusion 382
 damage control resuscitation (DCR) 388
 fresh frozen plasma (FFP) 386
 massive transfusion (MT) 388
 naturally occurring antibodies 383, 384, **384**
 packed RBCs (pRBCs) 382–383
 plasma products 386
 platelets 387–388
 pre-transfusion testing 382–384
 prevalence of 383, **384**
 storage lesions 385
 transfusion administration 384–385
 transfusion for exsanguinating hemorrhage 388
 transfusion reactions **385**, 385–386
 Trauma Associated Severe Hemorrhage Score (TASH) 388
 types of blood products 382, **383**
 bupivacaine 164, 167–168
 buprenorphine 76, **76**, 80, 84–85, **85**
 buspirone 291
 butorphanol **76**, 78, 80, 86, **86**
 butyropheneone drugs 55, 56
 BZ drugs *see* benzodiazepines drugs

C

calabadiol 218
 calcium channel blocker 242–243
 carbonic anhydrase inhibiting diuretics 316–317
 carprofen 140, 143–144
 catechol-O-methyl transferase (COMT) 24, 223
 cell-membrane drug transporters 13
 centrally acting muscle relaxant drugs
 see benzodiazepines;
 guaifenesin/glyceryl
 guaicolate (GG)
 cessation of drug effect(s) 3
 chloral hydrate 115
 chlorpromazine 56
 cimetidine 341, 342
 cisapride 354
 cisatracurium 207, **208**, 209
 clemastine 341
 clonidine 39, 293–294
 codeine 24
 combination of drugs 354
 corticosteroids 141

- COX-2 selective NSAIDs 139
 CW002 211, 218
 CYP450 enzymes 24
 CYP450 2D6 mutations 17
 cytochrome P450 1A gene
 expression 17–18
 cytochrome P450 2B
 enzymes 18–19
 cytochrome P450 2C enzymes 19
 cytochrome P450 2D
 enzymes 19–20
 cytochrome P450 2E enzymes 20
 cytochrome P450 3A enzymes 21
 differential expression of 16
 drug metabolism 15
 functional characteristics 15
 multiple isoforms of 15
 recombinant canine CYP450
 enzymes 16
 substrate specificity of 16
- d**
 debrisoquine/sparteine 14, 17
 depolarizing neuromuscular blocking
 agents *see* succinylcholine (SCh)
 deracoxib 144
 desflurane 41, 123, 128–130, 133
 chemical structures 124
 minimal alveolar concentration
 (MAC) of 127
 partition coefficients 126
 physicochemical properties 124
 detomidine 40–41
 dexmedetomidine 42–43
 diabetes mellitus, 357 *see also* insulin
 diazepam 187, 192, **193**
 anticonvulsant tolerance 68
 in cats 190–191
 dog metabolism 190
 empirical formula 67
 in humans 189
 legal status 67
 limitations of 67
 oral administration of 67
 pharmacokinetics in various
 species 62, **63–64**
 posology of 68, **68**
 rectal administration of 66
 in small ruminants 197
 US veterinary labeled products 67
 dihydropyridine calcium channel
 blockers 263
 diltiazem 261–262
- diphenhydramine 341
 discontinuation syndrome 296, **296**
 diuretics 243
 collecting ducts 321–322
 distal convoluted tubules
 potassium-sparing diuretics 321
 thiazide diuretics 320–321
 dopamine receptor agonists 322
 drug pharmacokinetics 315
 loop diuretics
 adverse effects 320
 mechanism of action 318
 pharmacokinetics 319, 319
 therapeutic uses 319–320
 pharmacology of 315
 proximal convoluted tubules
 carbonic anhydrase inhibiting
 diuretics 316–317
 osmotic diuretics 317–318
 dobutamine **224, 225**, 227–228, 228
 dopamine 221, 222, 222, **224**,
 225, 322
 pharmacodynamics 226–227
 dopamine receptors 222
 location and effects of 222, 223
 doxapram
 big potassium (BK) channels 177
 doses of 178, 179
 effects of 178, 179
 infusions of 178
 metabolism 178
 for neonatal resuscitation 178
 pre-Bötzinger complex 177
 TWIK-related acid sensitive K+
 channels (TASK) 177
 droperidol 57
 drug approval process for food
 animals 31
 drug elimination 3, 6, 33
 drug-transporter polymorphisms 21
- e**
 edrophonium 215–217, **217**
 electrolytes
 calcium 365–366
 magnesium 366–367
 potassium 363–365
 sodium 362–363
 elimination half-life ($t_{1/2}$), 4, 4–5, **5**, 9
 see also Individual entries
 amiodarone 260
 amlodipine 243
 atipamezole 45
- barbiturates 98, 99
 benazepril 241
 benzodiazepines 187, 289
 β -adrenergic antagonists 292
 buprenorphine 84 85
 buspirone 291
 butorphanol 86
 clonidine 39, 293
 deracoxib 144
 dexmedetomidine 42
 diazepam 189, 197
 doxapram 177
 endogenous insulin 357
 etomidate 113
 fentanyl 65, 83
 flumazenil 197
 flunixin meglumine 146
 gabapentin 294, 331, 332
 hydromorphone 81
 IM medetomidine 41
 ketamine 111
 ketoprofen 149
 levetiracetam (LV) 329
 lidocaine 257
 lorazepam 69
 losartan 242
 meperidine 83
 methadone 82
 methylphenidate 295
 midazolam 197
 monoamine oxidase inhibitors
 (MAOIs) 287
 nalbuphine 87
 naloxone 87
 non-steroidal anti-inflammatory
 drugs (NSAIDs) 139
 osmotic diuretics 317
 oxymorphone 83
 potassium bromide (KBr) 328
 prazosin 237
 propafenone 258
 romifidine 43
 selective serotonin reuptake
 inhibitors (SSRIs) 283
 sildenafil 272
 telmisartan 242
 tolazoline 44
 tramadol 308
 trazodone 290
 tricyclic antidepressants 286
 vatinoxan 45
 yohimbine 44
 zonisamide (ZN) 330

elimination rate constant 5
 enalapril 241
 endogenous catecholamines
 dopamine 221, 222, 226–227
 epinephrine (adrenaline) 221, 224
 norepinephrine
 (noradrenaline) 221, 224–226
 pathway of synthesis 221, 222
 pharmacokinetics 222–223
 structure 222–223, 222
 ephedrine (L-ephedrine) 229–230,
 224, 225, 228
 epinephrine (adrenaline) 221, 222,
 224, 224, 225
 esmolol 259
 esomeprazole 352, 354
 etodolac 144–145
 etomidate
 adrenocortical suppression 114
 cardiovascular effects 113–114
 central nervous system effects 114
 clinical uses 113, **114**
 contraindications 114–115
 drug interactions 115
 mechanism of action 113
 metabolism 113
 pharmacokinetics 113
 respiratory effects 114
 eutectic mixture of local anesthetics
 (EMLA) 166
 euthanasia 35
 extra-label drug use (ELDU) 31–32

f

“FDA approved” analgesic and
 anesthetic drugs 31
 FDA Center for Veterinary
 Medicine 31
 Federal Food, Drug and Cosmetic Act
 (FFDCA) 32
 feline hypokalemia 23
 fentanyl 80, **83**, 83–84
 Fick principle of diffusion 2
 firocoxib 145–146
 flecainide 258
 florphenicol (antibiotic) 35
 flumazenil 60, 66, 70, 197
 flunixin meglumine 35, 146–147
 Food Animal Residue Avoidance
 Databank (FARAD) 33
 food animals
 analgesic drugs 34–35

anesthetic drugs 34
 drug approval process 31
 drug tolerance 33
 euthanasia 35
 extended withdrawal interval
 (WDI) 33–34
 extra-label drug use (ELDU)
 31–32
 “FDA approved” analgesic and
 anesthetic drugs 31
 WDT withdrawal interval 32–33
 fraction of drug 5, **5**
 furosemide 318–320

g

gabapentin 294–295, 304–305,
 331–332
 gantacurium 211, 218
 German Shepherd dogs, sudden
 death of 23
 glomerular filtration rate (GFR) 3
 glyceryl guaiacolate (GG) *see*
 guaifenesin/glyceryl
 guaiacolate
 glyceryl trinitrate (GTN)
 cardiovascular effects of 268–269
 central nervous system
 effects of 269
 chemical synthesis of 266
 clinical use 268
 contraindications 269
 drug interactions 269
 effect on patients under general
 anesthesia 268
 mechanism of action 266, 267
 metabolism 268
 pharmacokinetics of 266–268
 respiratory system effects of 269
 grapiprant 147–148
 GTN *see* glyceryl trinitrate
 guaifenesin/glyceryl guaiacolate (GG)
 cardiovascular effects 185
 disadvantage 185
 doses 186
 formula of 184
 mechanism of action 183
 recovery 186
 recumbency 185
 vs. succinylcholine 183
 therapeutic index 184
 toxic signs 184
 triple drips 186, **186**, 187

h

halothane 39, 43, 57, 123, 125, 128,
 130–132, 178, 179, 224, 226–231,
 269, 273, 274, 286, 292
 chemical structure 124
 minimal alveolar concentration
 (MAC) of 40–42, 87, **127**,
 328, 363
 partition coefficients **126**
 physicochemical properties **124**
 Hetastarch 376
 Hoffman elimination 3
 hydromorphone 80, 81–82, **82**
 hydroxyzine 341
 hypercalcemia 365
 hyperkalemia 363–364
 hypernatremia 362, 363
 hypertonic crystalloids 373, 375
 hypocalcemia 365, 366
 hypokalemia 364–365
 hyponatremia 362, 363

i

idiogenic osmoles 362
 induction drugs
 alfaxalone 108–110, **109**
 alpha-chloralose 115
 chloral hydrate 115
 etomidate 113–115, **114**
 ketamine 110–113, **111, 113**
 propofol 106–108, **107**
 tiletamine 110–113, **111, 113**
 urethane 115
 infusion pharmacokinetics 8, 8–9
 inhalant anesthetics 123–133,
 358–359
 apneic index 131, **132**
 chemical structures 123, 124
 impact of 126
 minimal alveolar concentration
 (MAC) 125, 126, **127**, 128,
 128, 132
 partition coefficients 125, **126**
 pharmacodynamics
 cardiovascular system effects 131
 central nervous system
 effects 130–131
 effect on insulin 132
 hepatic effects 131
 musculoskeletal effects 132
 ocular effects 131
 renal effects 131–132

- respiratory system effects 131
 - pharmacokinetics
 - anesthetic uptake 129, 129–130
 - context-sensitive half-time 130
 - elimination 130
 - metabolism 130
 - partial pressure 129
 - physical and chemical
 - properties 123, **124**
 - boiling point 123–124
 - degradation 125
 - stability in soda lime 125
 - vapor pressure 124–125
 - potency 126, 128, **128**
 - solubility 126
 - injectable anesthetics 359
 - insulin
 - classification of 358, **358**
 - endogenous insulin 357
 - exogenous insulin
 - preparations 357–358
 - interactions with
 - alpha₂ adrenoceptor agonists 359
 - corticosteroids 359
 - inhalant anesthetics 358–359
 - injectable anesthetics 359
 - parasympathomimetics 359
 - parasympatholytics 359
 - sympathomimetics 359
 - tetracycline antibiotics 359
 - “loose” protocol 357
 - “tight” protocol 357
 - intranasal (IN) administration 2
 - intravenous (IV) administration 1–2
 - intravenous (IV) fluid therapy
 - adverse effects
 - acute kidney injury 376–377
 - coagulopathies 377
 - bloodwork parameters 370
 - commonly available fluids
 - 373, **374**
 - fluid responsiveness 370
 - fluid types
 - hypertonic crystalloids 373, 375
 - isotonic crystalloids 371–373
 - synthetic colloids 375–376
 - pulse pressure variation (PPV) 371
 - resuscitation endpoints 370
 - stroke volume variation (SVV) 371
 - systolic pressure variation (SPV) 371
 - ionizable drugs distribution 1
 - isoflurane 44, 57, 66, 78, 83, 130–132, 178, 179, 186, 196, 209, 210, 225–231, 295, 332, 334, 358, 359, 367, 372, 376
 - chemical structure 124
 - hemorrhagic shock model 230
 - minimal alveolar concentration (MAC) of 40–43, 86, 87, 123, **127**, 128, 130, 167, 196, 290
 - partition coefficients **126**
 - physicochemical properties **124**
 - isoproterenol (isoprenaline) 227
 - isotonic crystalloids
 - adverse effects 372–373
 - composition 371
 - dosing 372
 - pharmacology 371
 - ivermectin 21
- k**
- ketamine 306, 333
 - cardiovascular effects 111–112
 - central nervous system effects 112
 - clinical uses 111, **111**
 - contraindications 112, **113**
 - dissociative anesthesia 112
 - drug interactions 113
 - mechanism of action 110
 - metabolism 111
 - pharmacokinetics 110–111
 - respiratory effects 112
 - ketoprofen 35, 149–150
- l**
- lenperone 57
 - levetiracetam (LV) 329–330
 - lidocaine 6, 167, 257
 - lipophilic drugs 3
 - local anesthetics
 - additives 165
 - amide-linked local anesthetics **166**
 - bupivacaine 167–168
 - lidocaine 167
 - mepivacaine 167
 - ropivacaine 167
 - chemical structure of 166
 - ester-linked local anesthetics 166
 - nerve blockade 165
 - nerve classification 165, **165**
 - neural blockade 164
 - pharmacology of 164
 - pregnancy 166
 - site of injection 165
 - toxicity of 166
- loop diuretics
 - adverse effects 320
 - mechanism of action 318
 - pharmacokinetics 319, 319
 - therapeutic uses 319–320
- lorazepam (Ativan)
 - chemical name (IUPAC) 69
 - elimination half time 189
 - empirical formula 69
 - legal status 69
 - onset of action 189
 - pharmacokinetics in various
 - species 62, **64**
 - posology of **68**, 69
 - US veterinary labeled products 69
- losartan 242
- lysine-deficient 4 protein kinase (WNK4) function 23
- m**
- magnesium sulfate 243
 - mannitol 317–318
 - maropitant
 - mechanism of action 350
 - pharmacodynamics 350–351
 - pharmacokinetics 350, **351**
 - medetomidine 41–42
 - meloxicam 35, 150–151
 - meperidine (pethidine) 80, 82, **82**
 - mepivacaine 167
 - methadone 80, 82, **82**, 307–308
 - methohexital 96–100, 103–104
 - methylnaltrexone 88
 - methylphenidate 295–296
 - methylxanthines 179–180
 - metoclopramide 353–354
 - metoprolol 260
 - mexiletine 257–258
 - midazolam 187, 192, **193**
 - advantage 69
 - in alpacas 191, 197
 - in cats 190, 193, 195
 - chemical name (IUPAC) 68
 - clinical efficacy of 65
 - in dogs 190, 193–195
 - empirical formula 68
 - in horses 191, 196
 - in humans 189
 - intranasal administration of 66
 - intranasal bioavailability of 65

midazolam (*cont'd*)
 legal status 69
 pharmacokinetics in various
 species 62, **64**
 posology of **68**, 69
 in rabbits 195–196
 in rodents 195–196
 in small mammals 195–196
 in small ruminants 197
 US veterinary labeled products 69
 mineralocorticoid antagonists 321–322
 mivacurium 208
 monoamine oxidase inhibitors
 (MAOIs) 223, 287–288
 morphine 24, 80, 80–81, **81**

n

nalbuphine 87
 nalmefene 88
 naloxone 80, 87–88
 naltrexone 88
 neostigmine 215–217, **217**
 neuromuscular blocking
 agents (NMBAs)
 approximate duration of
 action 208, **208**
 in balanced anesthetic
 protocols 202
 clinical/surgical blockade 202
 depolarizing neuromuscular
 blocking agents (*see*
 succinylcholine (SCh))
 neuromuscular function
 monitoring 203–205, 204, 205
 non-depolarizing neuromuscular
 blocking agents (*see*
 benzylisoquinolinium)
 onset time 202
 potency 202
 recommended doses 208, **208**
 recovery index 202
 risks 202
 neuromuscular junction
 (NMJ) 202, 202
 New Animal Drug Application
 (NADA) 31
 nicotinic acetylcholine receptors
 (nAChR) 202
 nitric oxide (NO) 275–276
 nitrous oxide (N₂O) 123, 269–271, 273
 analgesia 133
 cardiorespiratory effects 133
 chemical structure 124

closed gas spaces 132
 diffusion hypoxia 133
 minimal alveolar concentration
 (MAC) of **127**
 partition coefficients **126**
 physicochemical properties **124**
 second gas effect 132
 N-methyl-D-aspartate (NMDA)
 antagonists
 amantadine 305–306
 ketamine 306
 non-depolarizing neuromuscular
 blocking agents *see also*
 acetylcholinesterase (AChE)
 inhibitors; benzylisoquinolinium
 CW002 211, 218
 gantacurium 211, 218
 non-steroidal anti-inflammatory drugs
 (NSAIDs)
 acetaminophen 139, 141–142
 adverse effects
 coagulation 140
 gastrointestinal 139–140
 kidney 140
 liver 140
 aspirin 140, 142–143
 carprofen 143–144
 chemical structure 139
 corticosteroids 141
 COX-2 selective NSAIDs 139
 deracoxib 144
 etodolac 144–145
 firocoxib 145–146
 flunixin meglumine 146–147
 in food and fiber animals 138
 grapiprant 147–148
 ketoprofen 149–150
 legal responsibility 138
 mechanism of action 139
 meloxicam 150–151
 pharmacology 138–139
 phenylbutazone 151–152
 piroxicam 152–153
 robenacoxib 153–154
 norepinephrine (noradrenaline) 221,
 224–226
 NSAIDs *see* non-steroidal
 anti-inflammatory drugs

o

omeprazole 352, 353
 ondansetron 351–352
 opioid agonist-antagonists

butorphanol 80, 86, **86**
 nalbuphine 87
 pentazocine 87
 opioid agonists 76, **77**
 cardiovascular effects 77–78
 central nervous system sedation
 and excitation 77
 chemical structures 80, 80
 fentanyl 80, **83**, 83–84
 gastrointestinal effects 78–79
 hydromorphone 80, 81–82, **82**
 integumentary effects 79
 meperidine (pethidine)
 80, 82, **82**
 methadone 80, 82, **82**
 minimum alveolar concentration
 (MAC) reduction 79
 morphine 80, 80–81, **81**
 nervous system effects 76
 ocular effects 77
 oral opioid agonist drugs 84
 oxymorphone 83
 remifentanyl **83**, 84
 respiratory effects 78
 with sedatives 79–80
 with selective serotonin reuptake
 inhibitors (SSRIs) 80
 thermoregulatory effects 79
 ultra-potent agonists 84
 urinary effects 79
 opioid antagonists
 methylnaltrexone 88
 nalmefene 88
 naloxone 87–88
 naltrexone 88
 opioid partial agonist 84–85, **85**
 opioids 23–25, 75–88
 agonist-antagonists
 butorphanol 80, 86, **86**
 nalbuphine 87
 pentazocine 87
 agonists 76, **77**
 cardiovascular effects 77–78
 central nervous system sedation
 and excitation 77
 chemical structures 80, 80
 fentanyl 80, **83**, 83–84
 gastrointestinal effects 78–79
 hydromorphone 80, 81–82, **82**
 integumentary effects 79
 meperidine (pethidine) 80,
 82, **82**
 methadone 80, 82, **82**

- minimum alveolar concentration (MAC) reduction 79
 - morphine 80, 80–81, **81**
 - nervous system effects 76
 - ocular effects 77
 - oral opioid agonist drugs 84
 - oxymorphone 83
 - remifentanyl **83**, 84
 - respiratory effects 78
 - with sedatives 79–80
 - with selective serotonin reuptake inhibitors (SSRIs) 80
 - thermoregulatory effects 79
 - ultra-potent agonists 84
 - urinary effects 79
 - antagonists
 - methylnaltrexone 88
 - nalmefene 88
 - naloxone 87–88
 - naltrexone 88
 - buprenorphine 76, 80, 84–85, **85**
 - distribution of 76
 - endogenous and exogenous ligands 75, **76**
 - hepatic biotransformation 76
 - mechanism of action 75
 - naloxone 76
 - opioid partial agonist 84–85, **85**
 - orally administered opioids 75
 - pharmacokinetics 75–76
 - receptor subtype 75, **76**
 - transdermal (TD) application 75
 - ultrapotent opioids 75
 - oral opioid agonist drugs 84
 - osmotic demyelination syndrome 362
 - osmotic diuretics 317–318
 - oxazepam 187, 189
 - oxybarbiturates 96, 100
 - oxymorphone 83
- p**
- pantoprazole 352
 - PB *see* phenobarbital
 - penile paralysis 56, 57
 - Pentastarch (Pentaspán®) 376
 - pentazocine 87
 - pentobarbital 35, 96, 97, 104
 - peripheral vasodilators
 - doses and uses of 266, **267**
 - glyceryl trinitrate (GTN)
 - cardiovascular effects of 268–269
 - central nervous system
 - effects of 269
 - chemical synthesis of 266
 - clinical use 268
 - contraindications 269
 - drug interactions 269
 - effect on patients under general anesthesia 268
 - mechanism of action 266, 267
 - metabolism 268
 - pharmacokinetics of 266–268
 - respiratory system effects of 269
- nitric oxide 275–276
- sildenafil
 - cardiovascular system effects of 273–274
 - central nervous system
 - effects of 274
 - clinical use 273
 - contraindications 275
 - drug interactions 275
 - effect on patients under general anesthesia 273
 - mechanism of action 272
 - metabolism 272–273
 - pharmacokinetics 272
 - respiratory system effects of 274
- sodium nitroprusside (SNP)
 - during cardiopulmonary resuscitation (CPR) 271
 - cardiovascular system effects of 270–271
 - central nervous system
 - effects of 271
 - clinical use 270
 - contraindications 271–272
 - drug interactions 272
 - effect on patients under general anesthesia 270
 - mechanism of action 269
 - metabolism 270
 - pharmacokinetics 269–270
 - respiratory system effects of 271
- P-glycoprotein (P-gp) transporter
 - 1, 21–23, 76
- pharmacodynamics *see also* Individual entries
 - definition 9
 - drug-receptor
 - interactions 10, 10–11
 - G protein-coupled receptor (GPCR) 9, 9–10
- pharmacogenetics *see also* Individual entries
 - ABCB1Δ mutation 22, 23
 - acetaminophen 14
 - ivermectin drugs 14
 - CYP450 enzymes
 - CYP450 2D6 mutations 17
 - cytochrome P450 1A gene
 - expression 17–18
 - cytochrome P450 2B
 - enzymes 18–19
 - cytochrome P450 2C enzymes 19
 - cytochrome P450 2D
 - enzymes 19–20
 - cytochrome P450 2E enzymes 20
 - cytochrome P450 3A enzymes 21
 - differential expression of 16
 - drug metabolism 15
 - functional characteristics 15
 - multiple isoforms of 15
 - recombinant canine CYP450
 - enzymes 16
 - substrate specificity of 16
 - debrisoquine/sparteine 14, 17
 - drug-transporter
 - polymorphisms 21
 - early human studies of 13
 - genetic variations 16–17
 - genome-wide association studies 13–14
 - ivermectin 21, 22
 - membrane-bound transporters 21
 - multi-modal techniques 14
 - P-glycoprotein (P-gp)
 - transporters 21–23
 - pre-therapy genetic screening 13
 - warfarin polymorphisms 14
- pharmacokinetics *see also* Individual drug entries
 - apparent volume of distribution (V) 3–4
 - clearance (CL)
 - hepatic clearance (CL_H) 6
 - rate of elimination 5
 - renal clearance (CL_R) 6–7
 - total body clearance 6
 - volume of distribution 5
 - compartmental models 7, 7
 - distribution 2–3
 - drug elimination 3
 - elimination half-life (t_{1/2}) 4, 4–5, 5
 - infusion pharmacokinetics 8, 8–9
 - metabolism (biotransformation) 3

- phenobarbital (PB) 96, 97, 102
 - clinical use and efficacy 326
 - cost and availability 325
 - drug interactions 327–328
 - mechanism of action 325
 - pharmacokinetics 325–326
 - side effects 327
 - toxicity 327
- phenothiazine *see* acepromazine
- phenylbutazone 35, 151–152
- phenylephrine (m-Synephrine, neosynephrine) 228–229
- phenytoin 258
- physostigmine 217
- piroxicam 152–153
- plasma concentration of drug vs. time 4, 4
- potassium bromide (KBr) 326, 328–329
- potassium-sparing diuretics 321
- potency 10, 10–11, 81, 82, 84, 87, 96, 97, 111
 - inhalant anesthetics 126, 128, **128**
 - neuromuscular blocking agents (NMBAs) 202
- pregabalin 304–305
- procainamide 256
- prodrugs 3
- prokinetics 353–354
- promazine 57
- propafenone 258
- propofol 1, 106–110
 - cardiovascular effects 107
 - central nervous system (CNS) effects 107–108
 - clinical uses 107, **107**
 - contraindications 108
 - drug interactions 108
 - mechanism of action 106
 - metabolism 107
 - myoclonus 108
 - pharmacokinetics 106–107
 - propofol infusion syndrome (PRIS) 108
 - respiratory effects 107
- propofol infusion syndrome (PRIS) 108
- propranolol 259
- prostaglandin receptor antagonists 309
- proton pump inhibitors (PPI) 352–353
- provisional acceptable residue (PAR) strategy 33, 34
- q**
- quinidine 255–256
- r**
- ranitidine 341
- remifentanyl **83**, 84
- remimazolam (CNS 7056) 69–70, 187
- renal elimination 3, 149
- resiniferatoxin (RTX) 310
- robenacoxib 153–154
- rocuronium 210–211
- romifidine 43–44
- ropivacaine 167
- s**
- SCh *see* succinylcholine
- selective serotonin reuptake inhibitors (SSRIs)
 - clinical use 283
 - contraindications 284
 - drug interactions 284–285
 - effects on organ systems 284
 - effects on patients under general anesthesia 285
 - mechanism of action 283
 - metabolism 283
 - pharmacokinetics 284
 - serotonin syndrome 284
- sevoflurane 6, 42, 125, 131, 190, 227, 328, 358
 - biotransformation 132
 - chemical structure 124
 - minimal alveolar concentration (MAC) of **127**, 128, 167, 308, 351
 - partition coefficients **126**
 - physicochemical properties **124**
 - recovery time 130
- sildenafil
 - cardiovascular system effects of 273–274
 - central nervous system effects of 274
 - clinical use 273
 - contraindications 275
 - drug interactions 275
 - effect on patients under general anesthesia 273
 - mechanism of action 272
 - metabolism 272–273
- pharmacokinetics 272
 - respiratory system effects of 274
- sodium nitroprusside (SNP)
 - during cardiopulmonary resuscitation (CPR) 271
 - cardiovascular system effects of 270–271
 - central nervous system effects of 271
 - clinical use 270
 - contraindications 271–272
 - drug interactions 272
 - effect on patients under general anesthesia 270
 - mechanism of action 269
 - metabolism 270
 - pharmacokinetics 269–270
 - respiratory system effects of 271
- sotalol 261
- SNP *see* sodium nitroprusside
- SSRIs *see* selective serotonin reuptake inhibitors
- statistical pharmacokinetic software 7
- succinylcholine (SCh)
 - clinical use 206
 - contraindications 206
 - effects on organ systems 206
 - mechanism of action 205
 - metabolism 205
- sugammadex 218
- sympatholytic drugs
 - α_2 -adrenergic receptor antagonists 240
 - non-selective α_1 - and α_2 -adrenergic receptor antagonists
 - phenoxybenzamine 238–239
 - phentolamine 239–240
 - selective α_1 -adrenergic receptor antagonists
 - doxazosin 237
 - prazosin 236–237
 - terazosin 237
- sympathomimetics
 - endogenous catecholamines
 - dopamine 221, 222, 226–227
 - epinephrine (adrenaline) 221, 224
 - norepinephrine (noradrenaline) 221, 224–226
 - pathway of 221, 222
 - pharmacokinetics 222–223
 - structure 222–223

- synthetic catecholamines
 dobutamine 227–228, 228
 isoproterenol (isoprenaline) 227
 pharmacokinetics 222–223
 structure 222–223
 synthetic non-catecholamines
 ephedrine (L-ephedrine)
 229–230, 228
 pharmacokinetics 222–223
 phenylephrine (m-Synephrine,
 neosynephrine) 228–229
 structure 222–223
 synthetic colloids 375–376
- t**
- tapentadol (TAP) 308–309
 TCAs *see* tricyclic antidepressants
 telmisartan 242
 temazepam 187
 terbutaline 231
 tetracycline antibiotics 359
 Tetrastarch (Voluven® or
 Vetstarch®) 376
 thiamylal 96
 thiazide diuretics 320–321
 thiobarbiturates 96, 98
 thiopental 96–103, 98
 tiletamine **109**, 110–113, **113**
 cardiovascular effects 111–112
 central nervous system effects 112
 clinical uses 111, **111**
 contraindications 112, **113**
 dissociative anesthesia 112
 drug interactions 113
 mechanism of action 110
 metabolism 111
 pharmacokinetics 110–111
 respiratory effects 112
 tolazoline 44–45
 topiramate 331
 tramadol 307–308
 Trauma Associated Severe Hemorrhage
 Score (TASH) 388
 trazodone
 clinical use 289–290
 contraindications 290
 drug interactions 290
 effect on patients under general
 anesthesia 290–291
 effects on organ systems 290
 metabolism 290
 pharmacokinetics 290
 tricyclic antidepressants
 (TCAs) 231, **285**
 clinical use 285
 contraindications 286
 drug interactions 286–287
 effect on patients under general
 anesthesia 287
 effects on organ systems 286
 metabolism 285
 pharmacokinetics 286
 side effects 286
 tripelethamine 341, 342
- u**
- ultra-potent opioid agonists 84
 urethane 115
- v**
- valid veterinary client-patient
 relationship (VCPR) 31, 32
 vasodilators, 243 *see also* peripheral
 vasodilators
 vasopressin (antidiuretic
 hormone) 222
 in CPR 230
 exogenous vasopressin 230
 location and effects of
 222, **223**
 receptor profiles 224, **224**
 recommended dosages for **225**
 in septic shock 230–231
 subtypes 230
 vatinoxan 45
 vecuronium 210
 ventricular arrhythmias 23
- w**
- warfarin polymorphisms 14
 weakly acidic drug 1
 whole genome sequencing 13
- x**
- xylazine 40, 41, 44, 45, 87, 186,
 285, 359
- y**
- yohimbine 44, 359
- z**
- zolazepam 60, 110, 111
 zonisamide (ZN) 330–331

